Pharmaceuticals News and Research

RSS

Florbetaben PET tracer data to be presented at Alzheimer's Association ICAD 2010

Bayer HealthCare Pharmaceuticals, Inc. today announced that data on the company's investigational PET amyloid imaging tracer Florbetaben (BAY 94-9172) will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu July 10 – 15.

9 Jul 2010

Renhuang signs Acquisition Agreement with Forest Bureau

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced that on July 8, 2010, the Company signed an Acquisition Agreement with Yichun Red Star Forest Bureau of Heilongjiang Province for indefinite exclusive access to 100,000 acres of wild Siberian Ginseng in Heilongjiang Province.

9 Jul 2010

Merck to lay off 15 percent of workers, close plants, research facilities

Drugmaker Merck announced it is closing eight research centers and eight manufacturing plants and laying off 15,000 people from its worldwide operations during the next two years because of its merger with Schering-Plough. "The restructuring is expected to save $2.7 billion to $3.1 billion in 2012, the company said. Meanwhile, the pretax cost of the initial phase of the cost-cutting program is expected to range from $3.5 billion to $4.3 billion, much of it in severance packages for employees."

9 Jul 2010

Second round of checks to close Medicare doughnut hole sent out

"The Obama administration is sending $250 checks to more than 300,000 older Americans who paid higher drug costs in the Medicare coverage gap known as the 'doughnut hole,' officials announced Thursday. The one-time, tax-free checks are the first tangible benefit of the health care package that became law this year."

9 Jul 2010

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

A new system for the controlled delivery of pharmaceutical drugs has been developed by a team of University of Rhode Island chemical engineers using nanoparticles embedded in a liposome that can be triggered by non-invasive electromagnetic fields.

9 Jul 2010

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.

9 Jul 2010

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

Merck & Co., Inc., Whitehouse Station, NJ, U.S., announced today plans to phase out the Merck Frosst Centre for Therapeutic Research, located at the head office of its Canadian subsidiary in Kirkland, Québec, by the end of 2010.

9 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces the achievement of regulatory and commercial milestones.

9 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

9 Jul 2010

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

There is plenty to worry about when it comes to the job of parenting. However, wondering if a child is receiving the correct amount of over-the-counter (OTC) medication can now be a concern of the past, thanks to Children's AccuDial(R), a patented new line of children's medication available across Canada, with a dosing system based on body weight, not age.

9 Jul 2010

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

The U.S. Food and Drug Administration today warned that Que She, marketed as an herbal weight loss supplement, contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions.

9 Jul 2010

WaferGen Biosystems announces closing of $7.2M registered direct offering

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced the closing of a $7.2 million registered direct offering. The amount raised includes $1 million from the Chairman and CEO, Alnoor Shivji, and approximately $500,000 in the aggregate from four other members of the board of directors of WaferGen.

9 Jul 2010

iPierian announces closing of $22M Series B equity financing round

iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.

9 Jul 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

Cannabis Science enters into long-term lease on 9,500 square foot facility in Denver, Colorado

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.

8 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Pharmaceuticals News and Research

Florbetaben PET tracer data to be presented at Alzheimer's Association ICAD 2010

Renhuang signs Acquisition Agreement with Forest Bureau

Merck to lay off 15 percent of workers, close plants, research facilities

Second round of checks to close Medicare doughnut hole sent out

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

WaferGen Biosystems announces closing of $7.2M registered direct offering

iPierian announces closing of $22M Series B equity financing round

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Cannabis Science enters into long-term lease on 9,500 square foot facility in Denver, Colorado

Calithera Biosciences completes Series A financing totaling $40M

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence